Chief Executive Officer
Bor-Wen Wu is an experienced scientist-entrepreneur who has helped develop numerous novel therapeutic candidates for high-need medical conditions. In 2006, he co-founded Polaris Group and its subsidiary, Polaris Pharmaceuticals, with the goal of advancing clinical development of ADI‑PEG 20, which had been in development at Phoenix Pharmacologics Inc. Dr. Wu previously founded TDW Pharmaceuticals, which develops treatments for cancer and gout, and DesigneRx Pharmaceuticals, which operates a cGMP facility for biologics in California. Earlier in his career, Dr. Wu spent 13 years as a biochemist at Agouron Pharmaceuticals, Warner-Lambert and Pfizer, where he made significant contributions to the development of Viracept, an HIV protease inhibitor that was approved in 1996. Dr. Wu earned his Ph.D. in Molecular Biology and Biochemistry from the University of California, Irvine.